Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-01-17, Stock:NVS, The news for the past five days is as follows:
2018-01-09: NEWS1: Ignyta’s Drug Pipeline.NEWS2: A Close Look at Ignyta’s Licensing Agreement.NEWS3: AbbVie Expects Peak Sales of $7 Billion for Imbruvica.NEWS4: Assessing Incyte’s 3Q17 Product Portfolio.NEWS5: Analyst Recommendations for Ignyta and Its Peers in January 2018.NEWS6: How Was Incyte’s Revenue Stream in 3Q17?.NEWS7: 5 Companies Hit 52-Week Highs.NEWS8: Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications.NEWS9: Valeant on the Street: Analyst Recommendations in December 2017.NEWS10: FDA Approvals Surge in 2017: Here's a Look at the Numbers.NEWS11: The Swiss Stock Market Broke Out To A New All-Time High.NEWS12: Novartis Announces Initiation Of SURPASS, Head-to-head Trial Of Cosentyx.
2018-01-10: NEWS1: Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018.NEWS2: Novartis becomes latest big-name collaborator for Chapel Hill company.NEWS3: Merck's Keytruda Combo Gets Breakthrough Therapy Status.NEWS4: Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar.NEWS5: Ignyta and Its Key Risks in 2018.NEWS6: Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology.NEWS7: Inside Ignyta’s Financial Performance.NEWS8: The Swiss Stock Market Pulled Back From Yesterday's New High.
2018-01-11: NEWS1: Parkinson's Disease Space Again Under Spotlight This Week.NEWS2: VEA, QWLD: Big ETF Inflows.NEWS3: VEU, NSRGY, NVS, TM: Large Inflows Detected at ETF.NEWS4: Approval of Alecensa in Europe Could Boost Roche’s Revenue Growth.NEWS5: The Swiss Stock Market Slid Further As Index Heavyweights Fall.NEWS6: Novartis Names Elizabeth Barrett CEO, Novartis Oncology - Quick Facts.
2018-01-12: NEWS1: The Key Challenges Teva Pharmaceutical Is Facing.NEWS2: Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod.NEWS3: Ligand (LGND) Inks Deal With Glenmark for OmniAb Platform.NEWS4: What Analysts Recommend for Roche in January 2018.NEWS5: Zelboraf Could Boost Roche’s Sales Growth in 2018.NEWS6: The Swiss Stock Market Climbed Friday, But Finished The Week Lower.
2018-01-16: NEWS1: 3 Biotech Stocks Start Healthy in '18: Will the Rally Last?.NEWS2: Stock Gains Vanish As Small Caps Reverse Lower.NEWS3: Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?.NEWS4: Novartis (NVS) Announces Acceptance of Humira BLA by the FDA.NEWS5: How Teva Pharmaceutical Plans to Improve Financial Profile.NEWS6: Novartis (NVS) Announces Acceptance of Humira BLA by the FDA.NEWS7: The Swiss Stock Market Fell Again As Roche Weighs.NEWS8: European Markets Finished Mixed Despite Dip In Euro.NEWS9: European Shares Inch Higher As Euro Rally Pauses.NEWS10: Sandoz: FDA To Review BLA For Proposed Biosimilar Adalimumab - Quick Facts.NEWS11: The Race To Find A Treatment For NASH.

Answer: Rise